Vertex Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	3,953	-535.6	3,620	3,322	2,342
Depreciation & Amortization	178.6	182	169.5	148.3	125.6
Other Amortization	31.2	25.2	11.8	-	-
Asset Writedown & Restructuring Costs	379	-	-	-	-
Loss (Gain) From Sale of Investments	-	-	-	149.1	-17.1
Stock-Based Compensation	685.9	698.5	581.2	491.3	441.4
Other Operating Activities	-397.4	-347.9	-579.1	-321.6	-143.3
Change in Accounts Receivable	-347.3	-99.3	-84.1	-358.6	-274.7
Change in Inventory	-524.2	-517.3	-322.9	-136.4	-92.8
Change in Accounts Payable	36.8	49.5	48.7	120.8	31.9
Change in Other Net Operating Assets	-364.4	52.3	92.6	715	230.4
Operating Cash Flow	3,631	-492.6	3,537	4,130	2,644
Operating Cash Flow Growth	-	-	-14.35%	56.23%	-18.75%
Capital Expenditures	-437.6	-297.7	-200.4	-204.7	-235
Cash Acquisitions	-	-	-	-295.9	-
Sale (Purchase) of Intangibles	-	-187.7	-58	-	-
Investment in Securities	-483.1	-3,231	-2,852	227.3	-105.9
Other Investing Activities	-24.7	-54	-31	-47.8	-
Investing Cash Flow	-945.4	-3,770	-3,142	-321.1	-340.9
Long-Term Debt Issued	-	-	-	-	28.3
Total Debt Issued	-	-	-	-	28.3
Long-Term Debt Repaid	-5.4	-33.6	-44.9	-85.5	-47
Total Debt Repaid	-5.4	-33.6	-44.9	-85.5	-47
Net Debt Issued (Repaid)	-5.4	-33.6	-44.9	-85.5	-18.7
Issuance of Common Stock	127.7	114.6	134.6	186.3	102
Repurchase of Common Stock	-2,387	-1,582	-653.7	-172	-1,561
Other Financing Activities	3.7	6.2	1.8	3.5	-
Financing Cash Flow	-2,261	-1,495	-562.2	-67.7	-1,478
Foreign Exchange Rate Adjustments	90.9	-42.6	26.9	-29.2	-13.4
Net Cash Flow	515.6	-5,800	-139.7	3,712	811.2
Free Cash Flow	3,194	-790.3	3,337	3,925	2,409
Free Cash Flow Growth	-	-	-14.99%	62.97%	-19.55%
Free Cash Flow Margin	26.61%	-7.17%	33.81%	43.95%	31.80%
Free Cash Flow Per Share	12.38	-3.06	12.81	15.15	9.27
Cash Interest Paid	12.4	30.5	43.1	52.3	56.3
Cash Income Tax Paid	1,567	1,082	1,677	1,058	476.3
Levered Free Cash Flow	2,573	2,800	3,510	3,307	2,402
Unlevered Free Cash Flow	2,581	2,819	3,538	3,342	2,441
Change in Working Capital	-1,199	-514.8	-265.7	340.8	-105.2

Updated Feb 12, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q